References
1. Rehman A. Acute immune thrombocytopenic purpura in children. Turk J Hematol. 2007;24:41-51.
2. Bussel JB MC. Lanzkowsky’s Manual of Pediatric Hematology and Oncology 6th ed. ed: Elsevier; 2016.
3. Sandoval C, Visintainer P, Ozkaynak MF, Tugal O, Jayabose S. Clinical features and treatment outcomes of 79 infants with immune thrombocytopenic purpura. Pediatric blood & cancer. 2004;42(1):109-12.
4. Masamune Higashigawa TM, Ayako Yoshino, Kazuyuki Matsuda, Mitsue Ito, Tomoaki Maji and Ryouji Ichimi. Incidence of childhood primary immune thrombocytopenic purpura. Pediatrics International 2015;57:1041–3. doi: doi: 10.1111/ped.12788.
5. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kühne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93. Epub 2008/11/14. doi: 10.1182/blood-2008-07-162503. PubMed PMID: 19005182.
6. Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. British journal of haematology. 2003;122(5):818-24.
7. Bolton-Maggs P. Idiopathic thrombocytopenic purpura. Archives of disease in childhood. 2000;83(3):220-2.
8. Beck CE, Nathan PC, Parkin PC, Blanchette VS, Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr. 2005;147(4):521-7. Epub 2005/10/18. doi: 10.1016/j.jpeds.2005.04.032. PubMed PMID: 16227040.
9. Bansal D, Bhamare TA, Trehan A, Ahluwalia J, Varma N, Marwaha RK. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2010;54(3):403-7. Epub 2009/11/13. doi: 10.1002/pbc.22346. PubMed PMID: 19908301.
10. D’Orazio JA, Neely J, Farhoudi N. ITP in children: pathophysiology and current treatment approaches. Journal of pediatric hematology/oncology. 2013;35(1):1-13.
11. Kühne T. Advances in chemical pharmacotherapy for the treatment of pediatric immune thrombocytopenia. Expert Opinion on Pharmacotherapy. 2018;19(7):667-76. doi: 10.1080/14656566.2018.1458091.
12. Kühne T. Treatment of pediatric primary immune thrombocytopenia with thrombopoietin receptor agonists. Semin Hematol. 2015;52(1):25-30. Epub 2015/01/13. doi: 10.1053/j.seminhematol.2014.10.004. PubMed PMID: 25578416.
13. Ehrlich LA, Kwitkowski VE, Reaman G, Ko CW, Nie L, Pazdur R, Farrell AT. US Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia. Pediatric blood & cancer. 2017;64(12):e26657.
14. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A. Thrombopoietin receptor agonist use in children: data from the pediatric ITP consortium of North America ICON2 Study. Pediatric blood & cancer. 2016;63(8):1407-13.
15. Lee MS, Kim WC. Intracranial hemorrhage associated with idiopathic thrombocytopenic purpura: report of seven patients and a meta-analysis. Neurology. 1998;50(4):1160-3. Epub 1998/05/05. doi: 10.1212/wnl.50.4.1160. PubMed PMID: 9566417.
16. Heitink-Pollé KM, Nijsten J, Boonacker CW, de Haas M, Bruin MC. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis. Blood. 2014;124(22):3295-307. Epub 2014/10/12. doi: 10.1182/blood-2014-04-570127. PubMed PMID: 25305206.
17. Kühne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR, Group ICIS. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. The lancet. 2001;358(9299):2122-5.
18. Deel MD, Kong M, Cross KP, Bertolone SJ. Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children. Pediatr Blood Cancer. 2013;60(12):1967-74. Epub 2013/09/17. doi: 10.1002/pbc.24628. PubMed PMID: 24038723.
19. Farhangi H, Ghasemi A, Banihashem A, Badiei Z, Jarahi L, Eslami G, Langaee T. Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old. Iranian journal of pediatric hematology and oncology. 2016;6(1):24.
20. Akbayram S, Dogan M, Ustyol L, Akgun C, Peker E, Bilici S, Caksen H, Oner AF. The clinical outcome of 260 pediatric ITP patients in one center. Clin Appl Thromb Hemost. 2011;17(6):E30-5. Epub 2010/08/18. doi: 10.1177/1076029610379849. PubMed PMID: 20713486.
21. Tamminga R, Berchtold W, Bruin M, Buchanan GR, Kühne T. Possible lower rate of chronic ITP after IVIG for acute childhood ITP an analysis from registry I of the Intercontinental Cooperative ITP Study Group (ICIS). Br J Haematol. 2009;146(2):180-4. Epub 2009/05/27. doi: 10.1111/j.1365-2141.2009.07743.x. PubMed PMID: 19466971.
22. Yacobovich J, Revel-Vilk S, Tamary H. Childhood immune thrombocytopenia–who will spontaneously recover? Semin Hematol. 2013;50 Suppl 1:S71-4. Epub 2013/05/17. doi: 10.1053/j.seminhematol.2013.03.013. PubMed PMID: 23664522.
23. Baronci C, Pansini V, Funaro D, Coletti V, Caruso R, Rossi GD. Idiopathic thrombocytopenic purpura (ITP) in children. Pediatric blood & cancer. 2006;47(S5):665-7.
24. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114(23):4777-83. Epub 2009/09/22. doi: 10.1182/blood-2009-04-215525. PubMed PMID: 19767509; PMCID: PMC2786288.
25. Sabhan AH, Al-Jadiry MF, Ghali HH, Abed WM, Al-Hadad SA. Chronic immune thrombocytopenic purpura in children overview of 60 patients. Pediatric Hematology Oncology Journal. 2016;1(1):9-12.
26. Oved JH, Lee CS, Bussel JB. Treatment of children with persistent and chronic idiopathic thrombocytopenic purpura: 4 infusions of rituximab and three 4-day cycles of dexamethasone. The Journal of pediatrics. 2017;191:225-31.
27. Liang Y, Zhang L, Gao J, Hu D, Ai Y. Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One. 2012;7(5):e36698. Epub 2012/06/06. doi: 10.1371/journal.pone.0036698. PubMed PMID: 22666325; PMCID: PMC3364261.
28. Sato T, Morita I, Fujita H, Ono M, Kimishima A, Tomiyama J, Murota S. Pharmacological characterization of cepharanthin in chronic idiopathic thrombocytopenic purpura. Platelets. 2001;12(3):156-62. Epub 2001/04/17. doi: 10.1080/09537100120039334. PubMed PMID: 11304417.
29. Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N, Araki R, Ota Y, Fujiwara M, Miyajima Y. High‐dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. Pediatrics International. 2017;59(3):303-8.
30. Tarantino MD, Bussel JB, Blanchette VS, Despotovic J, Bennett C, Raj A, Williams B, Beam D, Morales J, Rose MJ, Carpenter N, Nie K, Eisen M. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10039):45-54. Epub 2016/04/23. doi: 10.1016/s0140-6736(16)00279-8. PubMed PMID: 27103127.
31. Bussel JB, de Miguel PG, Despotovic JM, Grainger JD, Sevilla J, Blanchette VS, Krishnamurti L, Connor P, David M, Boayue KB. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. The Lancet Haematology. 2015;2(8):e315-e25.
32. Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. The Lancet. 2015;386(10004):1649-58.